Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on March 9, 2026, covering events that occurred on March 6, 2026. The filing details a series of material definitive agreements and amendments with key investors, including Uptown Capital, LLC, Streeterville Capital, LLC, and Iliad Research and Trading, L.P., aimed at restructuring debt obligations and terminating equity warrants.
Key Financial Metrics and Debt Restructuring
The filing does not provide standard operating metrics such as revenue, profit, or cash flow. Instead, it focuses on the restructuring of specific debt instruments and royalty interests:
- Uptown 2020 Royalty Interest: The Royalty Repayment Amount was reduced by 10% to $11,125,282.54. Monthly royalty payments are postponed from April 1, 2026, to July 1, 2026.
- Streeterville 2022 Royalty Interest: The Royalty Repayment Amount was reduced by 10% to $12,428,782.20. Monthly royalty payments are postponed from April 1, 2026, to July 1, 2026.
- 2021 Secured Promissory Note: The Outstanding Balance was reduced by 10% to $6,596,304.11. The maturity date was extended to July 1, 2026.
- 2025 Secured Promissory Note: The Outstanding Balance is $7,048,021.86. The maturity date was extended to March 12, 2029.
- Warrant Termination: Warrants exercisable for an aggregate of 48,211 shares of Common Stock were terminated.
Material Changes Versus Prior Period
The primary material changes involve the reduction of principal repayment obligations and the extension of payment timelines:
- Debt Reduction: A 10% reduction in the outstanding balance or repayment amount was applied to the Uptown 2020 Royalty, Streeterville 2022 Royalty, and the 2021 Note.
- Liquidity Extension: The commencement of monthly royalty payments was delayed by three months (from April to July 2026), and the maturity of the 2025 Note was extended by approximately three years.
- Collateralization: A new Security Agreement was executed, granting Streeterville a security interest in specific collateral (Lechlemer and TDPRV Collateral) to secure the 2025 Note.
Outlook, Risks, and Management Commentary
Management has secured immediate liquidity relief by deferring royalty payments and reducing principal balances. The extension of the 2025 Note maturity to 2029 provides a longer runway for the company. The termination of warrants reduces potential future dilution. The filing does not contain explicit forward-looking guidance regarding revenue or product milestones, nor does it detail specific risks beyond the obligations inherent in the amended agreements.
Investor Verification Checklist
- Verify the exact terms of the "Lechlemer Collateral" and "TDPRV Collateral" defined in the Security Agreement (Exhibit 10.1).
- Confirm the impact of the 10% debt reduction on the company's balance sheet and potential accounting treatment (e.g., gain on debt extinguishment).
- Review the full text of the Global Amendments (Exhibits 4.1 and 4.2) for any covenants or default triggers associated with the deferred payment dates.
- Assess the remaining cash flow requirements for the 2021 Note maturing in July 2026 versus the extended 2025 Note.